|
|
Office Locations:
|
Gustav Mahlerplein 102 Toyo lto Building, 20th Floor
Amsterdam, 1082 MA
The Netherlands
| |
|
|
|
|
|
|
Information Technology
Life Sciences & Healthcare
|
|
|
|
MS Ventures is the corporate venture arm of the biopharmaceutical division of Merck KGaA. The firm seeks to invest globally in early-stage biotechnology companies. Along with EUR 300 million through the MS Ventures fund, MS Ventures also manages the EUR 30 million Entrepreneur Partnership Program fund. This program was established to support the creation of spin-offs and the EUR 10 million Israel Bioincubator Fund, focused on pre-seed and seed opportunities coming out of Israel.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
